3795 related articles for article (PubMed ID: 32353859)
21. Data and Text Mining Help Identify Key Proteins Involved in the Molecular Mechanisms Shared by SARS-CoV-2 and HIV-1.
Tarasova O; Ivanov S; Filimonov DA; Poroikov V
Molecules; 2020 Jun; 25(12):. PubMed ID: 32604797
[TBL] [Abstract][Full Text] [Related]
22. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Fantini J; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 Aug; 56(2):106020. PubMed ID: 32405156
[TBL] [Abstract][Full Text] [Related]
23. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
[TBL] [Abstract][Full Text] [Related]
24.
Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
[TBL] [Abstract][Full Text] [Related]
25. Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective.
Hosoki K; Chakraborty A; Sur S
J Allergy Clin Immunol; 2020 Aug; 146(2):285-299. PubMed ID: 32624257
[TBL] [Abstract][Full Text] [Related]
26. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.
Martorana A; Gentile C; Lauria A
Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574
[TBL] [Abstract][Full Text] [Related]
27. Anti-SARS-CoV-2 Potential of Artemisinins In Vitro.
Cao R; Hu H; Li Y; Wang X; Xu M; Liu J; Zhang H; Yan Y; Zhao L; Li W; Zhang T; Xiao D; Guo X; Li Y; Yang J; Hu Z; Wang M; Zhong W
ACS Infect Dis; 2020 Sep; 6(9):2524-2531. PubMed ID: 32786284
[TBL] [Abstract][Full Text] [Related]
28. Repurposing old drugs as antiviral agents for coronaviruses.
Yang CW; Peng TT; Hsu HY; Lee YZ; Wu SH; Lin WH; Ke YY; Hsu TA; Yeh TK; Huang WZ; Lin JH; Sytwu HK; Chen CT; Lee SJ
Biomed J; 2020 Aug; 43(4):368-374. PubMed ID: 32563698
[TBL] [Abstract][Full Text] [Related]
29. The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19.
Yoshimoto FK
Protein J; 2020 Jun; 39(3):198-216. PubMed ID: 32447571
[TBL] [Abstract][Full Text] [Related]
30. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
Giovane RA; Rezai S; Cleland E; Henderson CE
Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275
[TBL] [Abstract][Full Text] [Related]
31. Drug targets for COVID-19 therapeutics: Ongoing global efforts.
Saxena A
J Biosci; 2020; 45(1):. PubMed ID: 32661214
[TBL] [Abstract][Full Text] [Related]
32. Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19).
Yuan S; Chan CC; Chik KK; Tsang JO; Liang R; Cao J; Tang K; Cai JP; Ye ZW; Yin F; To KK; Chu H; Jin DY; Hung IF; Yuen KY; Chan JF
Viruses; 2020 Jun; 12(6):. PubMed ID: 32532085
[TBL] [Abstract][Full Text] [Related]
33. In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2.
Pizzorno A; Padey B; Dubois J; Julien T; Traversier A; Dulière V; Brun P; Lina B; Rosa-Calatrava M; Terrier O
Antiviral Res; 2020 Sep; 181():104878. PubMed ID: 32679055
[TBL] [Abstract][Full Text] [Related]
34. Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro When Administered After Virus Infection.
Clementi N; Ferrarese R; Criscuolo E; Diotti RA; Castelli M; Scagnolari C; Burioni R; Antonelli G; Clementi M; Mancini N
J Infect Dis; 2020 Aug; 222(5):722-725. PubMed ID: 32559285
[TBL] [Abstract][Full Text] [Related]
35. Statin therapy and SAR-COV-2: an available and potential therapy?
Abdel-Latif RG; Mohammed S; Elgendy IY
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):333-334. PubMed ID: 32379307
[No Abstract] [Full Text] [Related]
36. Antiviral activities of type I interferons to SARS-CoV-2 infection.
Mantlo E; Bukreyeva N; Maruyama J; Paessler S; Huang C
Antiviral Res; 2020 Jul; 179():104811. PubMed ID: 32360182
[TBL] [Abstract][Full Text] [Related]
37. Perspectives for repurposing drugs for the coronavirus disease 2019.
Cherian SS; Agrawal M; Basu A; Abraham P; Gangakhedkar RR; Bhargava B
Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):160-171. PubMed ID: 32317408
[TBL] [Abstract][Full Text] [Related]
38. Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters.
Yuan S; Wang R; Chan JF; Zhang AJ; Cheng T; Chik KK; Ye ZW; Wang S; Lee AC; Jin L; Li H; Jin DY; Yuen KY; Sun H
Nat Microbiol; 2020 Nov; 5(11):1439-1448. PubMed ID: 33028965
[TBL] [Abstract][Full Text] [Related]
39. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
40. Computational Identification of Human Biological Processes and Protein Sequence Motifs Putatively Targeted by SARS-CoV-2 Proteins Using Protein-Protein Interaction Networks.
Nadeau R; Shahryari Fard S; Scheer A; Hashimoto-Roth E; Nygard D; Abramchuk I; Chung YE; Bennett SAL; Lavallée-Adam M
J Proteome Res; 2020 Nov; 19(11):4553-4566. PubMed ID: 33103435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]